Clinical Pharmacokinetics of Atomoxetine

@article{Sauer2005ClinicalPO,
  title={Clinical Pharmacokinetics of Atomoxetine},
  author={John-Michael Sauer and Barbara J. Ring and Jennifer Wright Witcher},
  journal={Clinical Pharmacokinetics},
  year={2005},
  volume={44},
  pages={571-590}
}
Atomoxetine (Strattera®), a potent and selective inhibitor of the presynaptic norepinephrine transporter, is used clinically for the treatment of attention-deficit hyperactivity disorder (ADHD) in children, adolescents and adults. Atomoxetine has high aqueous solubility and biological membrane permeability that facilitates its rapid and complete absorption after oral administration. Absolute oral bioavailability ranges from 63 to 94%, which is governed by the extent of its first-pass metabolism… Expand
Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.
TLDR
The present review attempts to revisit and analyze all published clinical pharmacokinetic data on atomoxetine inclusive of public access documents from the new drug application submitted to the United States Food and Drug Administration (FDA). Expand
Effects of CYP2C19 Genetic Polymorphisms on Atomoxetine Pharmacokinetics
TLDR
It is suggested that the genetic polymorphisms of CYP2C19 significantly affect the pharmacokinetics of atomoxetine. Expand
Metabolic profiling of norepinephrine reuptake inhibitor atomoxetine.
  • K. Mackenzie, Mingkun Zhao, +5 authors F. Li
  • Medicine, Chemistry
  • European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences
  • 2020
TLDR
The findings concerning aldehydes should be very useful to further elucidate the mechanistic aspects of adverse effects associated with ATX from metabolic angles to investigate the contribution of specific metabolites to ATX toxicity and possible drug-drug interactions in suitable models. Expand
Dihydroxyphenylglycol as a Biomarker of Norepinephrine Transporter Inhibition by Atomoxetine: Human Model to Assess Central and Peripheral Effects of Dosing
TLDR
The data suggest that DHPG is a useful biomarker to proactively assess the pharmacological activity of compounds intended to inhibit NET activity within the brain and shows that CSF is a medium for early identification and quantification of biomarkers useful in assessing novel neuroscience targets. Expand
Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers.
  • I. Todor, A. Popa, +6 authors C. Briciu
  • Medicine
  • Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques
  • 2016
TLDR
The effect of bupropion on CYP2D6 activity was responsible for an increased systemic exposure to atomoxetine and also for a decreased exposure to its main metabolite, 4-hydroxyatomxetine-O-glucuronide. Expand
Physiologically based pharmacokinetic modelling of atomoxetine with regard to CYP2D6 genotypes
TLDR
This model could be utilized for identification of appropriate dosages of atomoxetine in patients with reduced CYP2D6 activity to minimize the adverse events, and to enable personalised medicine. Expand
Atomoxetine and Duloxetine: Evaluation of a Potential Pharmacokinetic Drug-Drug Interaction
Abstract Objective: The present research aimed to investigate whether a pharmacokinetic drug interaction exists between atomoxetine, a substrate of CYP2D6 and duloxetine, an enzymatic inhibitor ofExpand
The Influence of CYP2D6 Phenotype on the Pharmacokinetic Profile of Atomoxetine in Caucasian Healthy Subjects
TLDR
It was demonstrated that the metabolic phenotype significantly influenced atomoxetine pharmacokinetics, as PMs presented a 4.5-fold higher exposure to the parent drug and a 3.2-fold lower exposure to its metabolite in comparison to EMs. Expand
Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers
TLDR
FVX had a modest effect on the pharmacokinetics of ATX and 4-hydroxyatomoxetine-O-glucuronide, and the presence or absence of any clinical consequences associated with this pharmacokinetic drug-drug interaction needs to be established in future studies. Expand
Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele.
TLDR
The pharmacokinetics of atomoxetine in healthy Chinese subjects appears comparable to other ethnic populations, and multiple dosing of 80 mg qd atomxetine was well tolerated in this study. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 76 REFERENCES
Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism.
TLDR
The role of the polymorphic cytochrome p450 2D6 (CYP2D6) in the pharmacokinetics of atomoxetine hydrochloride has been documented following both single and multiple doses of the drug. Expand
Atomoxetine Hydrochloride: Clinical Drug-Drug Interaction Prediction and Outcome
In the studies reported here, the ability of atomoxetine hydrochloride (Strattera) to inhibit or induce the metabolic capabilities of selected human isoforms of cytochrome P450 was evaluated.Expand
Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
  • S. Preskorn
  • Biology, Medicine
  • Clinical pharmacokinetics
  • 1997
TLDR
An overview of the clinically relevant pharmacology of selective serotonin reuptake inhibitors (SSRIs) with an emphasis on their pharmacokinetics and effects on cytochrome P450 (CYP) enzymes is presented. Expand
Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog.
TLDR
Although subtle differences were observed in the excretion and biotransformation of atomoxetine in rats and dogs, the primary difference observed between these species was the extent of first-pass metabolism and the degree of systemic exposure to atomxetine and its metabolites. Expand
Effect of Potent CYP2D6 Inhibition by Paroxetine on Atomoxetine Pharmacokinetics
TLDR
It was concluded that inhibition of CYP2D6 by paroxetine markedly affected atomxetine disposition, resulting in pharmacokinetics similar to poor metabolizers of CYp2D 6 substrates. Expand
Identification of the human cytochromes P450 responsible for atomoxetine metabolism.
TLDR
It is indicated that in patients with compromised CYP2D6 activity, multiple low-affinity enzymes will participate in the formation of 4-hydroxyatomoxetine, and coadministration of P450 inhibitors to poor metabolizers of CYP1D6 substrates would not be predicted to decrease the clearance of atomxetine in these individuals. Expand
Inhibition of alprazolam and desipramine hydroxylation in vitro by paroxetine and fluvoxamine: comparison with other selective serotonin reuptake inhibitor antidepressants.
In vitro preparations of human liver microsomes were used to study the inhibiting effects of two selective serotonin reuptake inhibitor (SSRI) antidepressants, paroxetine and fluvoxamine, onExpand
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation.
TLDR
These findings are consistent with published case reports describing SSRI-related increments in plasma phenytoin levels, and fluvoxamine can be expected to have the highest probability of interfering with the metabolism of CYP2C9 substrates. Expand
Inhibition of CYP2C9 by selective serotonin reuptake inhibitors: in vitro studies with tolbutamide and (S)-warfarin using human liver microsomes
TLDR
Fluvoxamine was shown to be the most potent inhibitor of both tolbutamide 4-methylhydroxylation and (S)-warfarin 7-hydroxyation, consistent with in vivo data indicating that amongst the SSRIs, fluvoxamines has the greatest potential for inhibiting CYP2C9-mediated drug metabolism. Expand
Atomoxetine Increases Extracellular Levels of Norepinephrine and Dopamine in Prefrontal Cortex of Rat: A Potential Mechanism for Efficacy in Attention Deficit/Hyperactivity Disorder
TLDR
It is hypothesized that the atomoxetine-induced increase of catecholamines in PFC, a region involved in attention and memory, mediates the therapeutic effects of atomxetine in ADHD. Expand
...
1
2
3
4
5
...